Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: A comparison between escitalopram and other SSRI/SNRIs

Journal of Medical Economics

Volumn 12, Issue 2, 2009, Pages 124-135

  Wu, Eric Q ^a,c   Greenberg, Paul E ^a   Yang, Elaine ^a   Yu, Andrew P ^a   Ben Hamadi, Rym ^a   Erder, M Haim ^b  

^a ANALYSIS GROUP   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Cost; Escitalopram; Healthcare utilisation; MDD; SNRI; SSRI; Treatment persistence

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PRESCRIPTION; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CITALOPRAM; COSTS AND COST ANALYSIS; DATABASES AS TOPIC; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 67749119872     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903093537     Document Type: Article

References (42)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-3105. (Pubitemid 37432885)
2. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005;65(16):2379-2404. (Pubitemid 41573609)
3. Bloom BS. Prevalence and economic effects of depression. Manag Care 2004;13(6 Suppl):9-16.
4. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64(12):1465-1475.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498- 1504
6. Nierenberg AA. Current perspectives on the diagnosis and treatment of major depressive disorder. Am J Manag Care 2001;7(11 Suppl):S353-366.
7. Anonymous. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157(4 Suppl):1-45.
8. Weilburg JB. An overview of SSRI and SNRI therapies for depression. Manag Care 2004;13(6 Suppl):25-33.
9. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A doubleblind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006;21(3):159-169. (Pubitemid 43740307)
10. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65(9):1190-1196.
11. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19(5):305-310.
12. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7(4 Suppl 1):40-44. (Pubitemid 34663207)
13. Hirschfeld RM, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004;65(4 Suppl):46-52.
14. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31(2):122-131.
15. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19(3):149-155. (Pubitemid 38586486)
16. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59(3):268-275. (Pubitemid 40352741)
17. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50(1):57-64. (Pubitemid 38721171)
18. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20(3):131-137. (Pubitemid 40571510)
19. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23(7):1605-1614. (Pubitemid 47122170)
20. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21(5):297-309. (Pubitemid 44162482)
21. Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs 2004;18(7):469-473
22. Demyttenaere K, Hemels ME, Hudry J, Annemans L. A costeffectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27(1):111-124. (Pubitemid 40342582)
23. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin. Jun 2004;20(6):869-878.
24. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18(13):911-932. (Pubitemid 39612019)
25. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21(4):631-642. (Pubitemid 40676116)
26. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23(2):155-167 (Pubitemid 40460655)
27. Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998;47(6):446-452. (Pubitemid 29011124)
28. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care 1996;2:1239-1246. (Pubitemid 126477345)
29. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23(7):934-942.
30. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63(4):619-630. (Pubitemid 32695143)
31. Simon GE, Katon WJ, Lin EH, et al. Diabetes complications and depression as predictors of health service costs. Gen Hosp Psychiatry 2005;27(5):344-351.
32. Kalsekar ID, Madhavan SM, Amonkar MM, et al. The effect of depression on healthcare utilization and costs in patients with type 2 diabetes. Manag Care Interface 2006;19(3):39-46.
33. The International Classification of Diseases, 9th Revision, Clinical Modification. 4 edn. Washington, DC: The U.S. Department of Health and Human Services, 1991.
34. McCombs JS, Luo M, Johnstone BM, Shi L. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000;3(3):222-231. (Pubitemid 30641385)
35. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613-619.
36. Anonymous. Patient compliance in depression. Am J Manag Care 2000;6(2 Suppl):S31-38.
37. Wu E, Greenberg P, Yang E, et al. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin 2008;24(10):2805-2813.
38. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005;27(4):486-496. (Pubitemid 40732655)
39. Burton WN, Chen CY, Conti DJ, et al. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care 2007;13(2):105-112.
40. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40(7-8):1280-1288.
41. Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care 2000;38(9):911-925.
42. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141(1 Suppl):S28-33. (Pubitemid 43028477)